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Abstract
Immunoinformatics is an emergent branch of informatics science that long ago pullulated from the tree of knowl-
edge that is bioinformatics. It is a discipline which applies informatic techniques to problems of the immune sys-
tem. To a great extent, immunoinformatics is typified by epitope prediction methods. It has found disappointingly
limited use in the design and discovery of new vaccines, which is an area where proper computational support is
generally lacking. Most extant vaccines are not based around isolated epitopes but rather correspond to chemi-
cally-treated or attenuated whole pathogens or correspond to individual proteins extract from whole pathogens or
correspond to complex carbohydrate. In this chapter we attempt to review what progress there has been in an as-
yet-underexplored area of immunoinformatics: the computational discovery of whole protein antigens. The effec-
tive development of antigen prediction methods would significantly reduce the laboratory resource required to
identify pathogenic proteins as candidate subunit vaccines. We begin our review by placing antigen prediction
firmly into context, exploring the role of reverse vaccinology in the design and discovery of vaccines. We also
highlight several competing yet ultimately complementary methodological approaches: sub-cellular location pre-
diction, identifying antigens using sequence similarity, and the use of sophisticated statistical approaches for pre-
dicting the probability of antigen characteristics. We end by exploring how a systems immunomics approach to
the prediction of immunogenicity would prove helpful in the prediction of antigens.
Vaccines, vaccination, and vaccinology: a brief
introductory orientation
Vaccines are agents – either molecular or supramolecu-
lar - which can stimulate protective immunity against
microbial pathogens and the diseases they cause. Protec-
tive immunity is a specific and enhanced adaptive
immune response to subsequent re-infection or, when
luck holds, infection by related organisms. Such aug-
mented immunity is mediated by the exacerbation of
immune memory, which militates against the effects of
infectious organisms. The word vaccine itself is derived
from vacca (Latin for cow). [1][2][3].
It is a thing of near universal agreement that mass
vaccination - synergising as it does with the herd immu-
nity it helps engender - is the most effective and effica-
cious prophylactic treatment currently available for
contagious disease. Humankind is commonly affected by
over seventy infectious diseases, many of which are or
will be targets for vaccines. There are in excess of fifty
licensed vaccines, half of which are deemed to be in
common use. Most vaccines prevent childhood infec-
tions or are used by travellers to tropical or subtropical
regions; only a minority combat disease in third-world
countries. As recently as the late 1960s, there were over
10 million cases of smallpox spread through 31 coun-
tries, with about two million deaths a year, yet now
smallpox is wholly and totally eradicated. Poliomyelitis
or Polio is the other key global disease close to eradica-
tion. In 1991, the Pan American Health Organization
eliminated polio from the Western Hemisphere. In the
First World, the annual death rate arising for contagious
diseases such as polio, diphtheria, or measles is less than
one in a thousand. The Global Polio Eradication Pro-
gram has now greatly reduced the prevalence of Polio in
the rest of the world. Only 784 cases of polio were
reported in 2003. Nevertheless, Polio remains endemic
in Nigeria, Afghanistan, Pakistan, and India.
Despite such outrageous and egregious success, many
major issues persist. No licensed vaccines exist for HIV
and malaria, two of the World Health Organization
* Correspondence: d.r.flower@aston.ac.uk
1School of Life and Health Sciences, University of Aston, Aston Triangle,
Birmingham, B4 7ET, UK
Full list of author information is available at the end of the article
Flower et al. Immunome Research 2010, 6(Suppl 2):S1
http://www.immunome-research.com/content/6/S2/S1
IMMUNOME RESEARCH
© 2010 Flower et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.(WHO)’s three big global killers, and there are no realis-
tic hopes for such vaccines appearing in the short to
medium term. Bacille Calmette Guérin (BCG), the only
vaccine licensed currently for the third major world dis-
ease, tuberculosis, has only limited efficacy [4]. Add to
this the 35 new, previously unknown infectious diseases
identified in the past 25 years: HIV, Marburg’s disease,
SARS, dengue, West Nile, and over 190 human infec-
tions with the potentially pandemic H5N1 influenza. It
is commonly believed that new contagious diseases will
continue to emerge in the 21st century. The world of
the 21st century is threatened by parasitic diseases and
emerging zoonotic infections; antibiotic-resistant bac-
teria; and bioterrorism [2]
The vaccine arena has long been neglected, partly as
a consequence of the extraordinary success just adum-
brated, but activity within it is now feverish and febrile
[5,6]. Dozens of vaccine candidates have passed
through phase II clinical trials, and during the past
decade, vaccines in late development have numbered
over 150. Unlike antibiotics, resistance to vaccines is
negligible. In the same way that vaccines target many
kinds of disease, themselves caused by microbial
pathogens of all types, so there are many types of fun-
damentally distinct vaccine. See Figure 1. These
include attenuated or inactivated whole pathogens,
subunit vaccines, peptide vaccines, and vaccines based
on carbohydrates, amongst others. Historically, the
most successful and prevalent types vaccines have been
those based on attenuated – that is “weaken” or non-
infective - whole pathogen vaccines, for example BCG
f o rT Bo rS a b i n ’s Polio vaccine. Safety concerns have
fomented other vaccine strategies to develop, which
focus on antigens and latterly epitopes as the intrinsic
component of single or composite vaccines. Hepatitis
B vaccine is an antigen - or subunit – based vaccine.
While many epitope-based vaccines have now entered
clinical trials, they are yet to fulfil their potential,
medically or commercially.
Antigens, immunogenicity, and subunit vaccines
Subunit vaccines are typically but not exclusively protein
molecules and their discovery is often based around a
somewhat haphazard, essentially empirical search for
antigenic or immunogenic protein antigens. The word
antigen has several meanings in immunology and thus
in vaccinology. The Oxford English Dictionary defines
an antigen as a “…foreign substance which, when
injected into an organism, stimulates antibody produc-
tion.” They trace its first use to 1908, and by the middle
of the century the word had found its way into common
technical dictionaries. An immunogen is on the other
hand: “Any substance capable of eliciting an immune
response”, although the word had other, earlier defini-
tions. Its first use in its modern rendering is traced to
1959, but was doubtless in use before then.
Figure 1 A schema summarising the components of a generic vaccine. The immunogenic component will typical be an attenuated or
chemically-inactivated microbe, a protein antigen, or a poly-epitope or conjugate. This component will be combined with an appropriate
delivery mechanism and an adjuvant. Delivery mechanisms and adjuvants overlap in their ability to increase the immunogenicity of a weakly-
active vaccine.
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meaning of scientific terms particularly well. So, to be
more precise, an immunogen, that is a moiety exhibiting
immunogenicity, is any substance able to elicit a specific
immune response, while an antigen - a moiety exhibit-
ing antigenicity - is a substance which is recognized by
an existing immune response, and its associated under-
lying molecular moieties such as T cells or antibodies,
in a recall response. Immunogenicity is the most impor-
tant and interesting property for vaccine design and dis-
covery. It is this property that allows a molecular moiety
to induce a significant immune response.
For the purposes of this review, our use of the terms
antigen and immunogen shall be restricted to a single
meaning; that of a protein, specifically one from a
pathogenic microorganism, that evokes a measurable
immune response. Currently, the prophylactic responses
of almost all effective vaccines – with the exception of
BCG which is mediated by the quadrille of interacting
antigen presenting cells (APCs), T-cells, and other pha-
gocytotic cells that characterise cellular immunity – are
mediated by humoral immunity and antibodies. The
pathogenesis of most diseases for which vaccines are not
currently available are typically if not exclusively
mediated by cellular immune mechanisms. Thus, when
seeking to identify immune responses for untreated dis-
ease, the immunogenicity sought need not be mediated
by antibodies; mediation by cellular mechanisms or a
combination of humoral and cellular mechanisms is
equally valid.
In what follows, we will endeavour to explore the
availability of informatic tools and techniques for the
identification of candidate subunit vaccines. Even today,
in the early years of the 21
st century, many experimental
scientists still retain an atavistic distrust of any and all
computational approaches. The very suggestion that
algorithms can help them, saving effort and time is an
anathema to them and their way of thinking, undermin-
ing all that they hold dear. They are deeply distrustful of
the reliability of computer methods, preferring what
they perceive as the infallible reliability of the experi-
ment. Not that they would admit to views so philosophi-
cally - and practically – naive; but deep down this is
how they think and how they feel. Yet things have chan-
ged and changed dramatically, and things will continue
so to change.
Reverse vaccinology and epitopes
Slowly but surely, reverse vaccinology is becoming a dis-
cernibly more prevalent means of identifying subunit
vaccines; and slowly but surely the contribution made
by computation to the practice of reverse vaccinology is
becoming ever more significant and ever more obvious
[7]. See Figure 2. Conventional laboratory-based,
experimental microbiological approaches to antigen
identification typically start with the cultivation of the
target pathogenic micro-organism under laboratory con-
ditions, then dissecting them into their component pro-
teins, assaying these in some cascade of in vitro and
in vivo assays, leading ultimately to the identification of
proteins which display requisite protective immunity. It
would indeed be wonderful if the identification of candi-
date vaccines was really and consistently this simple and
systematic? Unfortunately, it is often so much more
complex, confusing, and confounding. It is not always
possible to cultivate a particular pathogen outside of the
host organism. Many proteins are only expressed transi-
ently during the course of infection. Nor are all proteins
easily expressed in sufficient quantities in vitro.T h u s
many potential candidate vaccines may be missed.
Reverse vaccinology [7-10] is, by contrast, able to ana-
lyze a genome to identify potential antigens. Initially,
the pathogenic genome is scanned for “open reading
frames” or ORFs. Once all ORFs have been identified,
proteins are selected on the basis that they will be
accessible to immune system surveillance, usually using
some form of informatic-based prediction methodology
or, more likely, set of methdologies. Reverse vaccinology
was established by a group studying Neisseria meningiti-
dis, which is responsible for sepsis and meningococcal
meningitis. Vaccines are available for all serotypes
except subgroup B. Potential ORFs in N. meningitidis
genome were identified [11][12]; 570 proteins were iden-
tified, 350 expressed in vitro, and 85 were surface
exposed. Seven proteins conferred immunity over a
broad range of strains.
Another good example is Streptococcus pneumoniae,
a major cause of sepsis, pneumonia, and meningitis [13]
[14]. 130 potential ORFs were identified, 108 of which
could be expressed; six proteins were found to induce
protection. Another example is Porphyromonas gingiva-
lis, a gram-negative anaerobic bacterium found in sub-
gingival plaques present in chronic adult inflammatory
gum disease periodontitis. Of the 370 ORFS identified
in the genome [15], 120 protein sequences were pre-
dicted to be open to surveillance by the immune system,
40 were positive for one or more sera. When used to
vaccinate mice, two antigens exhibited clear protection.
This very brief survey highlights the potential for vac-
cine discovery using this approach. However, the num-
ber of potential antigens is still high, particularly when
we explore all potential difficulties in expressing and
characterising them. Both experimental and computa-
tional methodologies may thus omit potentially impor-
tant antigenic proteins from analysis, albeit for different
reasons, and both require continual optimisation. In
particular, bioinformatics support for preclinical vaccine
discovery has yet to flourish; but, as interest in vaccines
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nursery to at least the kindergarten. There are two main
forms of support for vaccine discovery provided by
bioinformatics. The first is technically indistinguishable
from support for more general target discovery, and
includes genomic annotation for both host and patho-
gen sequences and immunotranscriptomics, the applica-
tion of microarray analysis to the immune system. The
other type kind of support is focussed on immunoinfor-
matics: it addresses problems such as the accurate pre-
diction of epitopes.
Currently, prediction of T cell epitopes is essentially
confined to predictions of varying accuracy of peptide
binding to Major Histocompatibility Complex. Binding
of peptides to class I MHC are reasonably accurate, at
least for well characterised alleles [16]. However, several
comparative studies have shown recently that the pre-
diction of class II MHC binding prediction T-cell epi-
topes is typically poor [17][18][19], and likewise for
structure-driven prediction of MHC-mediated epitopes
[20][21]. Similarly, both structure- [22] and data-driven
[23] prediction of antibody-mediated epitopes is sub-
optimal. While the prediction of B cell epitopes remains
primitive, or depends on an oft elusive knowledge of
protein structure, methods for T cell epitopes prediction
displaying not inconsiderable algorithmic sophistication
have been and continue to be developed.
Despite this, and for different reasons, reliable and
consistent prediction remains somewhat elusive; this
regrettable decision will doubtless continue so for some
time. Ultimately, all methods, however sophisticated, are
severely circumscribed by the data used to propagate
and parameterise them. No data-driven method can go
beyond the data used to train it; all methods are likewise
much superior in their ability to interpolate than their
ability to extrapolate. It is only by compiling extensive,
high-quality data that we can aspire to create excellent
models of general applicability. What we require are sets
of data that are complete, thorough, and properly
thought through. Such sets would be able to explore
both efficiently and effectively the complex and con-
founding multi-dimensional phase space of properties
evinced by the molecules we target.
IEDB [24-29] is a step-change in this direction. IEDB
is the dominant force in current immunoinformatics
and stands as one of the principal achievements of the
field. The number and quality of epitopes within it are
an enormous improvement over all that has gone before.
Alex Sette and his co-workers are to be congratulated
on their achievement, but, like all dominant things,
IEDB has tended to choke most other efforts in the
field, and even IEDB has its limitations.
Data is usually multi-dimensional, and each dimension
will typically be correlated, to a greater or lesser extent,
with each other dimension. Together, these many
dimensions chart a space: a space of structural variation
or variation of properties. If the data we use is itself of
sufficient quality and provides a good enough coverage
Figure 2 Whole Antigen Discovery. Taking a reverse vaccinology dynamic, the process of discovering candidate subunit vaccines begins with
a microbial genome, perhaps newly sequence, progresses through an extensive computational stage, ultimately to deliver a shortlist of antigens
which can be validated through subsequent laboratory examination. The computational stage can be empirical in nature; this is typified by the
statistical approach embodied in vaxijen [98]. Or this stage can be bioinformatic; this involves predicting subcellular location and expression
levels and the like. Or, this stage can take the form of a complex mathematical model which uses immunoinformatic models combined with
mathematical methods, such as metabolic control theory [116], to predict cell-surface epitope populations.
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say, computer science - of which there are indeed very
many - are now of satisfactory accuracy to build models
of high predictive accuracy.
As we have said, there is an on-going need for the
quality, quantity, and availability of data to improve and
increase. Prediction is enthral to its underlying data.
Bias within the data places strict limitations upon the
interpretability and generality of models from which it is
derived. In general, for MHC-peptide binding experi-
ments, the sequences of peptides studied are very biased
in terms of amino acid composition, often favouring
hydrophobic sequences. This arises, in part, from pre-
selection processes that result in self-reinforcement.
Binding motifs are often used to reduce the experimen-
tal burden of epitope discovery. Very sparse sequence
patterns are matched and the corresponding subset of
peptides tested, with an enormous reduction in
sequence diversity.
Irrespective of their poor performance in prediction,
several other problems exist, albeit different for T- and
B-cell epitope prediction. For T-cell prediction, the key
issue is the availability of data. It has recently been
shown that T-cell epitopes, which were previously
thought to be short peptides of 8-10 amino acids, can
be up to 16 amino acids or perhaps even more. The
existence of these longmer epitopes has greatly
expanded the repertoire of peptides open to inspection
by T-cells [30][31][32][33]. Problematic as this seems,
the situation is made worse by the fundamental logistic
constraints of sampling within the specificity exhibited
by a single allele. The number of possible sequences
that a nonameric peptide might possess is in the region
of 512 billion; considering that a single model is built
from at most a few hundred peptides, the sampling
undertaken is infinitesimally small. Similarly, the 3000+
different MHC alleles known to exist in the global
human population indicates the extraordinary potential
for distinct peptide specificities within the potential
patient cohort.
For B-cell prediction, explaining the poor performance
of B-cell epitope prediction algorithms may point to a
fundamental misinterpretation of extant epitope data.
PEPSCAN is perhaps the most abundant data available
currently but may not be what it seems. Experimentally
derived epitopes are identified by being assayed against
pre-existing antibodies with affinity for whole antigens.
However, if such “epitopes” are mapped on to their par-
ent antigen structure they are randomly located
throughout the protein and do not equate to clear sur-
face patches, as one might expect if they simply mimic
discontinuous epitopes identified by crystallography;
in situ these antigenic regions can be completely buried,
and thus inaccessible to antibody binding, rather than
exposed. If we compare the conformation of antibody-
bound peptides with those from the intact antigens, they
are usually quite different. However, B-cell epitopes in
intact antigen and in whole antigen-antibody complexes
are similar. It may be that the preformed antibody
recognizes denatured antigen in vivo or that the isolated
peptide adopts a conformation able to mimic the surface
features of a discontinuous epitope.
Moreover, there is also evidence that the responsive-
ness of the immune system to pathogenic proteins is
only poorly correlated with the possession of T cell epi-
topes, and that many potential epitopes have been
deleted in proteins regularly accessible to immune sur-
veillance, perhaps as an evolutionary counter measure in
the war between host and pathogen [34]. Taken
together, these factors suggest that methods which rely
solely on the possession of epitopes are unlikely to be
fully effective when tasked with identifying antigens or
immunogens. This conjecture is confirmed by what
information there is, which indicates that there is little
simple correspondence between antigens selected on
this basis and experimentally verified antigenic or pro-
tective proteins.
Thus we must seek alternative methods for selecting,
and prioritising within that selection, proteins likely to
be antigenic and protective. We shall below examine
three key approaches: subcellular location prediction,
sequence similarity, and empirical statistical approaches,
typified by VaxiJen.
Identifying antigens through subcellular location
prediction
For a protein to be accessible to surveillance by the
immune system, it is often assumed to be physically
external to the microbial organism or at least present on
its surface rather than being sequestered away far from
the roving eye of the immune system. For bacteria this
means it must be secreted or located on - or in - the
outer membrane surface. In this context, immune sur-
veillance is undertaken by a variety of cellular and mole-
cular actors, but chiefly by neutralising antibodies. Thus
the goal of identifying antigens through the use of sub-
cellular location prediction is principally to identify sur-
face proteins accessible to binding by neutralizing
antibodies.
Unlike the relatively straightforward and well-studied
task of identifying ORFs, selecting the subcellular loca-
tion of proteins can be challenging to the point of con-
fusion. Nonetheless, and notwithstanding the obvious
caveats inherent in this strategy, this has become a
favoured approach taken by many when tasked with
selecting vaccine candidates.
We should remember, however, that antigens are not
epitopes, and epitopes are not antigens. So possession of
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dent of sub-cellular location, and they may in principle
be possessed by any protein. As we have said, there is
evidence for T-cell epitope depletion in pathogenic pro-
teins [35]; or it may be that just picking immune-acces-
sible proteins naturally favours proteins rich in antibody
and helper T-cell epitopes, as opposed to cytotoxic
T-cell epitopes, at least for membrane proteins. As data
accumulates on the specific responses made to differ-
ently located accessible proteins we can build these
recondite subtleties into prediction strategies.
There are two basic kinds of prediction method: man-
ual construction of rules of what determines subcellular
location and the application of data-driven machine
learning methods, which determine factors that discri-
minate between proteins from different known locations.
Accuracy differs markedly between different methods
and different compartments, mostly due to a paucity of
data. Data used to discriminate between compartments
include the amino acid composition of the whole pro-
tein; sequence-derived features of the protein, such as
hydrophobic regions; the presence of certain specific
motifs; or a combination thereof.
Databases, such as ProDom [36], Pfam [37], and PRO-
SITE [38], contain within them the capacity to identify
sequence motifs characteristic of certain protein families;
this can in turn help us to predict if a protein belongs to
an family of proteins which are typically extracellular.
However, gross sequence similarity alone is neither a
necessary nor a sufficient condition for a protein to share
a common sub-cellular location. Very similar sequences
may be located quite differently, while lack of similarity is
no guarantee that proteins will not be co-located. More-
over, many proteins can and do exist in several locations
within the cell, and often evince different if related func-
tions in these different locations [39]. Likewise, different
organisms, and specifically eukaryotes versus prokaryotes,
have quite different locations, both in number and in
physical nature. The number of such compartments used
in prediction studies varies considerably, and few papers
address the full rich complexity of cell biology. For exam-
ple, a common schema reduces eukaryotic cells to 4 com-
partments (cytoplasmic, extracellular, mitochondrial, and
nuclear) and prokaryotic to 3 compartments (cytoplas-
mic, extracellular, and periplasmic), though some papers
use over 10 compartments for eukaryotes. In fact, 10
compartments is an under-estimate, and the richness and
the complexity of sub-cellular location is daunting, since
any attempt to predict it must account for transient and
permanent location, multiple locations, and both mem-
brane organelles and multi-protein complexes as poten-
tial locales.
Among binary approaches, arguably the best method
is SignalP, which employs neural networks and predicts
N-terminal secretion signals cleaved by Signal Pepti-
dase-I-and their associated cleavage site [40-42] . The
signal predicted is the type II signal peptide common to
both eukaryotic and prokaryotic organisms, for which
there is a wealth of data, in terms of both quality and
quantity. A recent enhancement to SignalP is the imple-
mentation of a hidden Markov model (HMM) which
seeks to discriminate uncleaved signal anchors from
cleaved signal peptides. One of the limitations of SignalP
is overprediction, as it cannot reliably discriminate
between several very similar yet distinct signal
sequences, regularly predicting membrane proteins and
lipopteins as type II signals. Many other kinds of signal
sequence exist. A number of methods have been
developed to predict lipoproteins, for example. The pre-
diction of proteins that are translocated via the
TAT-dependent pathway is also important but has yet
to be addressed in any depth.
Many programs and servers have been devised and
developed able to predict the subcellular location of
gene products and proteins. PSORT is a well-known,
well-used example; it is knowledge-based, multicategory
prediction method, composed of several programs
[43-46]. PSORT I predicts 17 different subcellular com-
partments, while PSORT II predicts 10 locations. There
are several specialized versions of PSORT. iPSORT deals
specifically with secreted, mitochondrial, and chloroplast
locations. PSORT-B only predicts bacterial sub-cellular
locations. It reports precision values of 96.5% and recall
values of 74.8%. Another effective program is HensBC
[47]. This constructs a hierarchical ensemble of classi-
fiers by applying a series of if–then rules. HensBC is
able to assign proteins to one of four different types
(cytoplasmic, mitochondrial, nuclear, or extracellular)
with approximately 80% accuracy for gram-negative bac-
terial proteins. Another program is SubLoc [48], a cli-
ent/server suite which offers an interface for the
prediction of prokaryotic subcellular location in three
compartments. Another still is Gpos-PLoc [49], which
fuses many basic classifiers, engineered using the opti-
mized evidence-theoretic K-nearest neighbours rule.
Other programs include TatP 1.0 [50], LipoP 1.0 [51],
and Phobius [52]. This list goes ever on and on. A com-
parison of a subset of these programs, which used a test
set of 272 mycobacterial proteins [53], indicated that
subcellular localization methods generally had high pre-
dictive specificity and recognised true negatives reliably.
We have also developed a range of programs specifi-
cally aimed at addressing the prediction of subcellular
location within bacteria. Building on a set of algorithms
able to predict membrane proteins, TAT secretion, and
lipoproteins [54-60], a set of Bayesian networks, which
were able to make individual predictions for specific
subcellular locations was implemented in three pipelines
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with a confidence level-based decision engine and two
serial implementations with a hierarchical decision
structure [61]. These two hierarchies were rooted differ-
ently, one by prediction between membrane types and
the other by soluble versus membrane prediction. The
parallel pipeline outperformed the serial pipeline, but
took twice as long to execute. The soluble-rooted serial
pipeline outperformed the membrane-rooted predictor.
Assessment using genomic test sets was more equivocal,
as many more predictions are made by the parallel pipe-
line, yet the serial pipeline identifies 22 more of the 74
proteins of known location.
This work is indicative of a clear direction that the
development of future subcellular prediction strategies
might take. Currently, the richness of subcellular struc-
tures is yet to be integrated into location prediction.
Many cellular organelles are not included in such stu-
dies, nor are proteins with multiple locations, nor are
the different routes by which proteins can reach the
same compartment. The list of such caveats continues.
Clearly, if we can develop high specificity predictors for
each such compartment, then combining them appro-
priately [61], must be the way forward. There is then a
need for a more sophisticated phase of supervised learn-
ing, where better and more complete annotation is built
into any approaches taken.
Many difficulties remain however, most notably the
lack of validated, high quality datasets where the loca-
tion of proteins has been established unambiguously.
This paucity is particularly acute for certain important
but less well-studied kinds of secreted protein, such as
those secreted by the type III secretion system. While
databases such as DBSubLoc [62] have been developed,
their utility is open to question. So too is the extraction
of datasets directly from SWISS-PROT. Here the inher-
ent uncertainty in some of the available annotation can
be confounding or at least frustrating. Likewise, much
more work on the prediction of the subcellular location
of viral proteins is required; while some studies have
been undertaken [63][64], the complexity of their inter-
actions with their host organism must be factored into
future analyses. Generally, we can make the observation
that ignoring this complexity is, in trying to simplify
matters, more likely to render any analysis simplistic.
Fortunately, subcellular location prediction, useful
though it can be, and quibbles and cavils notwithstand-
ing, is not the only method available to us. There are
other weapons in our arsenal, many with an equal pro-
venance and of equal utility.
Identifying antigens through sequence similarity
One of the most obvious ways to identify new potential
antigens in newly sequenced microbial genomes is
through similarity searching. Assuming that we know the
sequence of one or more extant antigens, we can make
use sequence searching programs of various complexity
and sophistication, such as BLAST or FASTA, to identify
similar sequences in the target genome. This set of
selected candidate antigens c a nt h e nb ep r i o r i t i s e df o r
further theoretical and ultimately experimental valida-
tion. Obviously, all the same caveats that exist for any
sequence search hold here also: which thresholds are
appropriate? Are apparently high-scoring matches real or
an artefact of search methodology? This process also pre-
supposes that enough known antigens are available so
that such searches can be comprehensive and thus effec-
tive. Such compilation is the role played by the database.
In the last decade, factory-scale experimentation allied
to extensive literature mining has generated many func-
tional immunology databases. Databases, such as SYF-
PEITHI [65,66], which focus on properties of cellular
immunology, and look primarily at data relevant to
MHC processing, presentation, and T-cell recognition
have existed since the mid 1990s. Arguably, the best
such database is the HIV Molecular Immunology Data-
base [67], although clearly the depth of the database is
at the expense of breadth and generality. It archives
CD4+ and CD8+ T-cell and B-cell epitopes derived
from the virus. It also includes detailed biological infor-
mation regarding the response to the epitope, including
its impact on long term survival, common escape muta-
tions, whether an epitope is recognized in early infec-
tion, and curated alignments summarizing the epitope’s
global variability.
Other recent databases include MHCBN [68,69],
which contains 18,790 MHC-binding peptides, 3,227
MHC nonbinding peptides, 1,053 TAP binders and non-
binders, and 6,548 T-cell epitopes. EPIMHC [70] is a
relational database of naturally occurring MHC-binding
peptides and T-cell epitopes. Presently, the database
includes 4867 distinct peptide sequences from various
sources, including 84 tumor antigens. Two databases in
particular, warrant special attention, albeit for different
reasons. They are AntiJen [71], formerly known as Jen-
pep [72,73], and IEDB [24].
AntiJen seeks to integrate a wider range data than is
archived by other databases. Implemented as a relational
postgreSQL database, AntiJen is sourced from the pri-
mary literature and contains over 24,000 entries; it
includes quantitative kinetic, thermodynamic, functional,
and cellular data within the context of immunology and
vaccinology. As well as T-cell and MHC binding data,
AntiJen holds over 3,500 entries for linear and discon-
tinuous B-cell epitopes, and includes measurements of
peptide interactions with TAP transporter and peptide-
MHC complex interactions with T-cell receptors (TCR),
as well as immunological protein-protein interactions.
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addresses issues of biodefence. As we have said, it is on
a much larger scale than any other similar database, and
benefits significantly from the input of 13 dedicated epi-
tope sequencing projects. These exist, in part at least, to
populate the database. IEDB has largely eclipsed other
efforts in functional immune databases. However, it
does not, as a priority, address antigenicity at the whole
protein level.
At this point it is worth discussing the distinction
between functional annotation and the objective dis-
cussed here. Generally speaking, the function that a pro-
tein performs within the context of its organism of
origin is irrelevant to its status as an antigen. Here the
ubiquity and multiple meanings of the word antigen are
of little if any help. A protective antigen is a protein
which is recognised and recalled by the host. This char-
acteristic does not seem to be linked to the fact that a
protein is an enzyme or a DNA binding protein, nor
does logic require such a link. Thus identifying function
is not a necessary condition for a protein to be an anti-
gen, though the unequivocal identification of certain
functions, such as being a virulence factor for example,
greatly increases the probability that it will be such.
Concerning antigens, however, these databases,
although replete with information concerning individual
B cell epitopes, T cell epitopes, and Major Histocompat-
ibility Complex (MHC) binding peptides, remain other-
wise partial and incomplete. Their focus is on the
epitope, not the antigen. There are many antigens for
which specific epitope or MHC binding information is
not currently available, yet many such antigens are
known experimentally to induce either or both innate or
adaptive immune responses. Fortunately for the future
of vaccine design and discovery specific antigen-orien-
tated – rather than epitope-orientated - databases are
now becoming available.
Arguably, the clearest and most unequivocal example
of an antigenic protein is the so-called virulence factor
(VF). These proteins are able to undertake the coloniza-
tion of a host organism and/or induce disease. They are
the front-line weapons in the pathogenic arsenal. Analy-
sis of known pathogenic species, such as Vibrio cholerae
or Streptococcus pyogenes, has enabled the recognition
of recurrent “systems” of VFs and toxins that may total
40 or more distinct proteins. These may exist as discrete
pathogenicity islands or be spread more widely in the
genome.
Traditionally, classification of VFs has categorised
them as belonging to several thematic groups: adher-
ence/colonization factors, invasions, exotoxins, transpor-
ters, iron-binding siderophores, and miscellaneous cell
surface factors. A broader definition groups VFs into
three classes: (1) “true” virulence factors; (2) VFs
associated with the expression and regulation of class 1
VF genes; and (3) VFs required for the colonization of
the host [74].
A number of databases that archive VFs have been
reported. The Virulence Factor Database (VFDB; URL:
http://www.mgc.ac.cn/VFs/) contains 16 characterized
bacterial genomes with an emphasis on functional and
structural biology and can be searched using text,
BLAST, or functional queries [75,76]. TVFac (Los Ala-
mos National Laboratory Toxin and Virulence Factor
database; URL: http://www.tvfac.lanl.gov/) contains
genetic information on over 250 organisms and separate
records for thousands of virulence genes and associated
factors. The Fish Pathogen Database (URL: http://www.
fishpathogens.eu/vhsv/index.php), set up by the Bacter-
iology and Fish Diseases Laboratory, has identified over
500 virulence genes using fish as a model system. Patho-
gens studied include Aeromonas hydrophila, Edward-
siella tarda, and many Vibrio species. Candida albicans
virulence factor (CandiVF) is a small species-specific
database that contains VFs, which may be searched
using BLAST or a HLA-DR hotspot prediction server
[77]. PHI-base is a noteworthy development as it inte-
grates VFs into a cohesive whole a variety of pathogens
of plants and animals [78].
Obviously, antigens need not be VFs, they need only
be accessible to immune surveillance and need not be
directly or indirectly involved in infectivity. Because of
this, other types of database are required, able to cap-
ture and contain a wider tranche of relevant data. In the
recent past, another database has been developed: Anti-
genDB [79] contains a compilation of over 500 antigens
drawn from the literature and other immunological
resources. It marks a new beginning in immunoinfor-
matics, signalling a switch away from the peptide epi-
tope and toward the whole protein antigen. These
antigens come from 44 important pathogenic species. In
AntigenDB, a database entry contains information
regarding the sequence, structure, origin, etc. of an anti-
gen with additional information such as B and T-cell
epitopes, MHC binding, function, gene-expression and
post translational modifications, where available. Anti-
genDB also provides links to major internal and external
databases. AntigenDB will be updated on a rolling basis,
with the regular addition of antigens from other organ-
isms. This database will form the core of future attempts
to predict antigens both by sequence similarity and
using more recondite analysis.
At this point it is worth mentioning the issue of
thresholds. Clearly, when one runs a sequence search,
using BLAST for example, one might generate huge lists
of near-identical proteins or get no hits at all; and, for
that matter, we could also obtain almost any intermedi-
a t er e s u l t .T h ei s s u ei st oj u d g ew h i c hr e s u l ti su s e f u l
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threshold, above which we anticipate usefulness and
below which we might expect a lack of utility. Setting
such thresholds is however no easy task. They are
dependent on the nature of the family in question. For
the lipocalin family [80-82], for example, hits are still
valid in terms of structure and function at levels that
would simply be noise for most other protein families.
Thus thresholds are family dependent, as well as pro-
blem dependent. Empirically-selected cut-offs are thus
the order of the day, but much thought and experimen-
tation is needed in order to select appropriate values.
As well as seeking similarity to known antigens, there
is another, quite prevalent,i d e at h a ti sd e s e r v i n go f
comment: that the immunogenicity of protein is deter-
mined solely by its lack of similarity to the host. What
we search for is some quantitatively-meaningful measure
of the “foreignness” of a protein which correlates highly
with its immanent immunogenicity. In this context,
what we mean by the word “foreignness” is the evolu-
t i o n a r yd i s t a n c eb e t w e e nt h eh o s t– am a no rac o wo r
mouse - and the candidate antigen, or the organism that
produced it, or both. Some consider this to be the
prime factor determining the potential immunogenicity
of a protein [83,84]. Clearly, since we are dealing with
proteins and carbohydrates and the like, this evolution-
ary distance must be specified in terms of their molecu-
lar structures, or more likely their sequences, rather
than in terms of morphological features.
The potential importance of such a concept is sup-
ported by the observation that immune systems are
actively educated to lack reactivity when presented with
self-proteins [85], a process – often called immune tol-
erance – which is generated via epitope-specific
mechanisms including clonal anergy, receptor editing,
and clonal deletion [86][87]. But how can we progress
beyond this rather inexactly-specified philosophical
standpoint to something which is practically useful
when we select vaccine candidates?
A potentially more useful way to express this conjec-
ture is that the likelihood that a protein is immunogenic
is solely a function of that protein’s dissimilarity to the
whole host proteome at the sequence level. Or, to be
more precise, how close in terms of sequence similarity
is the candidate to the closest or most similar member
of the host proteome. Most sequence software is well
suited to solving this problem, since it is precisely this
problem that they were written to address. More diffi-
cult is assessing average dissimilarity to the whole pro-
teome, a problem compounded when we use the
similarity of overlapping peptide fragments rather than
looking at the similarity at the level of global sequence
alignment. In terms of choosing the length of such frag-
ments, the epitope would seem to be the most logical
choice, since this immunological quantum is the moiety
most likely to be recognised during the immune
response.
Yet even at the level of the epitope, a peptide of say
10 amino acids, even one mismatch in an otherwise per-
fect match can be significant, since such sequence dif-
ferences, comprising a single amino acid, may
exacerbate or abrogate neutralizing antibodies binding
to a particular antigenic protein. Moreover, the cross-
reactivity of a single high-affinity monoclonal antibody
is rather different in nature to the cross-reactivity of
large set of less affine polyclonal antibodies, and so too
their ability to tolerate amino acid mismatches. It will
also vary between individuals, since the immunization
history of each organism will dictate to a large extent
the recognition of epitopes.
Our understanding of epitopes can inform our under-
standing of mismatch tolerance, since the affinity of
T-cell epitopes is more dependent on the possession of
suitable anchor residues than it is on the possession of
non-anchor residues. Having said, the dogma of anchor-
dependent affinity was long ago debunked, since all resi-
dues make some kind of contribute to affinity, entropic
or enthalpic, although generally it is right to say that so-
called anchors do make more significant contributions.
Our understanding of the structural-basis that deter-
mines the affinity of antibody-mediated epitopes is
much less assured and complete, and the underlying
thermodynamic causes of affinity, if strict causes they
are, typically only become clear when high resolution
structural data combines with measured thermodynamic
metrics.
Likewise, when one looks not at a representative indi-
vidual, but at the whole population, then the deletion of
a single protein, within one host versus another, can
render candidates previously valid and immunogenic as
suddenly neither. Again, these are difficult issues; as yet,
they remain unresolved.
Given the hypothesis that immunogenicity is in some
sense mediated by the level of similarity between a
pathogenic protein and the host proteome, we have, in
as yet-unpublished work, sought to bench-mark
sequence similarity analysis as a means of quantifying
the differences between populations of antigens and
non-antigen. To that end, we identified sets of 100
known antigenic and 100 non-antigenic protein
sequences derived from a variety of sources: allergens,
bacteria, fungi, parasites, tumours and viruses. These
were compared to the human and mouse genomes
using standard sequence similarity searching protocols.
Whole pathogen proteomes were also aligned to these
host proteomes. Most antigenic and non-antigenic
sequences were observed to be non-redundant; this
implies a lack of clear homologues between pathogens
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of parasite antigens were found to have a much higher
level of similarity. These proteins comprised heat shock
proteins, catalases, and enzymes involved in hydrolysis.
These protein families are structurally conserved,
though they might display significant functionality
diversity.
We also used statistical approaches such as the non-
parametric Mann-Whitney test to assess if comparisons
between the two populations were significant. The sta-
tistical null hypothesis was accepted in most cases, sig-
nifying that the effect presumably resulted solely from
chance. The Mann-Whitney test supported the observa-
tions from sequence similarity analysis. We were unable
to determine a threshold or cut-off based on the
hypothesis of non-redundancy to the host’sp r o t e o m e .
These results suggest that this is not in itself a solution
to the identification of antigens. A variant based on
fragments may be more successful, and this is clearly an
issue crying out for further, deeper research.
There are, of course, many other ways to approaches
identifying antigenic proteins. One notable way, is look-
ing for the horizontal transfer of so-called pathogenicity
islands, clusters of pathogenic proteins acquired by
transfer between micro-organisms. Detection of such
islands, which are typically large gene clusters with an
atypical yet characteristic G + C content, can in turn
lead to the identification of antigenic proteins [88-91].
Analysis at the nucleic acid level rather than at the pro-
tein level can facilitate the discovery of virulence pro-
teins, perhaps using similar approaches to that used to
identify CpG islands [92][93][94][95].
However, rather than look at nucleic acid sequences,
or at protein sequences directly, a new approach, based
upon alignment-free techniques, has been developed
which shows significant potential; we examine this next.
Identifying antigens through empirical statistical
methods
Most in silico approaches to predicting antigens make
use of bioinformatics tools of one kind or another. Such
tools can identify membrane proteins, signal peptides, or
lipoproteins with some success, yet most algorithms still
rely on sequence alignment to identify characteristic
sequence relationships or motifs characteristic of anti-
gens. This may prove problematic in several ways. Some
proteins formed through divergent or convergent evolu-
tion lack obvious sequence similarity, although they may
share similar structures and/or biological properties
[96,97]. In such a situation, alignment-based approaches
may produce ambiguous results or fail spectacularly.
Many methods presuppose a direct sequence relation-
ship such as that which can be revealed by simple
sequence search techniques, such as BLAST. This is not
always the case. Immunogenicity, as a property, may
instead be encoded within the sequence and structure of
ap r o t e i ni ns u c hac r y p t i ca n ds u b t l em a n n e ra st og o
beyond the conventional limitations imposed when one
seeks direct identification by sequence alignment proto-
cols. Likewise, the discovery of truly novel antigens will
be frustrated by their lack of similarity to antigens of
known provenance.
As a departure from alignment-dependent techniques,
which dominate immunoinformatics as much as they do
bioinformatics, we have implemented an approach
which seeks to discriminate between candidate vaccines
and nonantigens, using an alignment-free sequence
representation [98,99]. Rather than concentrate on epi-
tope and nonepitope regions, the method uses data on
immunoprotective antigens derived from pathogenic
sources to derive statistical models for predicting whole-
protein antigenicity. In attempting to overcome the lim-
itations imposed by alignment-dependent sequence
similarity methods, we have implemented a novel align-
ment-independent method for antigen identification
based on auto cross covariance (ACC) transformation of
protein sequences into uniform equal-length vectors.
The ACC transform is a protein sequence mining
method originally devised by Wold et al. [100,101],
which has found much application to the quantitative
structure-activity relationships (QSAR) study of peptides
and also for the classification of proteins [102-109]. The
principal properties of the amino acids were represented
by z descriptors [110][111][112], which describe amino
acid hydrophobicity, molecular size and polarity. The
ACC transformation accounts for neighbour effects, i.e.
the lack of independence between different sequence
positions.
Initially, we sought to develop models able to distin-
guish immunoprotective proteins from the general
microbial proteome. We applied ACC pre-processing to
sets of known bacterial, viral and tumour antigens and
developed alignment-independent models for identifying
antigens. In a separate paper, extra models were added
which address fungal and parasite antigens. For bacter-
ial, viral and tumour antigens, models had prediction
accuracies in the 70% to 89% range [98,99][113]. For the
parasite and fungal antigens, models had good predictive
ability with 78% to 97% accuracy under internal cross
validation in 7 groups. Under external validation, they
gave 69% sensitivity ranking the true immunoprotective
proteins in the first 25% of their proteomes.
The models were implemented in a server for the pre-
diction of protective antigens and subunit vaccines,
which we have christened VaxiJen [98] (URL: http://
www.darrenflower.info/VaxiJen). The accuracy values
noted above are indicative of an approach that is more
accurate than has been seen before; for example, for
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ning; future research will yield significantly more insight
as the number of known protective antigens increases
[79].
Antigen selection and immunogenicity
There are several bioinformatics problems unique to
immunology: the foremost and greatest is the challenge
of accurately predicting immunogenicity. The successful
computational prediction of immunogenicity may mani-
fest itself at one extreme in the identification of a T-cell
or B-cell epitope. This is mediated by straightforward if
not uncomplicated molecular recognition events, which
can be understood through properly exploring relation-
ships between fundamental physical properties – hydro-
gen bonding and lipophilicity for example – and
apparent biological activity. Establishing such structure-
activity or property-activity relationships is a consider-
able concern of current immunoinformatics. At the
other extreme, we encounter an altogether more com-
plex phenomenon, where we see immunogenicity made
manifest in the accurate estimation of antigenicity at the
whole protein level. This is a system property; that is a
property of the whole immune system rather than an
individual molecular recognition event. At present, this
is very much a secondary aspect of modern day
immunoinformatics.
T h et a s ko fp r e d i c t i n gw h o l eprotein immunogenicity
is probably several orders of magnitude more complex
and demanding than say predicting the binding of pep-
tides to an MHC or even of predicting the binding of a
pMHC complex to a TCR. This is not to say that such
calculations are in any way trivial or lacking difficulty,
but rather than that such complex prediction exercises
are themselves subsumed in the task of predicting
immunogencity at the system level.
In our view, and in the view of other commentators,
the clinical manifestation of the immunogenicity of a
vaccine antigen, as opposed to the immunogenicity of
an isolated epitope, arises as the very complex amalgam
of many intertwining intrinsic and extrinsic factors,
operating at various length-scales and at various differ-
ent rates. Such factors include host-side properties and
pathogen-side properties, as well as protein-side proper-
ties that arise more or less exclusively from the protein
itself. See Figure 3.
So-called host-side properties are properties intrinsic
to the immune system of the host. They include the
possession of B-cell epitopes or T-cell epitopes, as
recognised by the adaptive immune system, or the pos-
session of Pathogen-associated Molecular Patterns or
PAMPs, which are recognised by Pattern Recognition
Receptors, such as Toll-like receptors (TLRs), part of
the innate immune system. Pathogen-side properties are
properties intrinsic to the pathogen as a whole organ-
ism. They include the expression level evinced by an
antigen, the time-course of its expression and secretion,
and also its subcellular location. Protein-side properties
include the state of aggregation exhibited by a candidate
vaccine and any post-translational danger signals that
the protein might possess. Some of these properties
have been discussed before. Thus one would expect, at
least naively, that a bona fide vaccine antigen would be
both highly expressed and available for immune surveil-
lance, as well as possessing epitopes that the host can
recognise, where as a protein which is not immunogenic
would lack such characteristics.
Identifying and predicting this diverse tranche of
properties is a problem and thus a challenge. Indeed,
each component part is a challenge unto itself. Consider
the prediction of a T cell epitope: the best understood
and most accurate of immunoinformatic prediction pro-
blems. Such an epitope needs to be processed properly
into a population of different peptides, and for the pro-
cessed peptides to exist in a reasonable amount, and
then be bound by an MHC with reasonable affinity,
before being recognized appropriately within the context
of a pMHC complex by a TCR. This then is a complex
and contingent process, similar to a generic Markov
process, comprised of many stages which are themselves
dependent on preceding steps. In terms of both
mechanism and what steps-within-steps there may be,
many of these steps are less than adequately understood.
However, each step remains amenable to statistical eva-
luation. All stages are inherently predictable given an
appropriate accumulation of relevant data.
The situation is very similar but not identical for bio-
pharmaceuticals. In this case, we can dispense with the
pathogen and replace it with several classes of extrinsic
factors which include amongst others product manufac-
ture, patient health, and medication strategy. Acute ill-
ness, particularly systemic illness, or latent bacterial or
viral infections such HCV, can have a most profound
effect on the manifestation of immunogenicity. Likewise,
ap a t i e n t ’s genetics may alter profoundly the immune
reaction to biopharmaceuticals, most obviously, the
MHC haplotype will affect host T-cell responses.
T h eN E R V Ep r o g r a mi sa ne x p e r ts y s t e mf o rv a c c i n e
antigen discovery, which addresses in a practical way
some of the issues of prioritisation discussed above. The
program has been developed to help automate the pro-
cess of reverse vaccinology [114]. The identification and
prioritising of potential ORFs using NERVE comprises 6
stages. Firstly, the prediction of subcellular localization;
then whether the protein is an adhesin; followed by the
identification of transmembrane domains; then the pro-
tein is compared with both the human and pathogen
proteomes; after which the protein is finally assigned a
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and ranked, and a list of proteins is produced graded by
precedence and the probability that it will be an immu-
nogenic antigen.
But NERVE and other extant programs, such as
DyNAVacS [115], tasked with such a confounding task
necessarily fall far short of what is needed or indeed
what is possible. There needs to be a concerted and far-
reaching effort to address this issue. The most direct
line of attack is to address first the subcellular location
issue, as we discussed above. Likewise, we can decon-
struct the antigen presentation pathway, building models
for each step and then integrating them into a fully
functional model. We can develop empirically-based,
statistically-grounded approaches - of which VaxiJen
[98,99,113] is merely the vanguard – that have their
basis in emerging antigen databases. Yet all of this is
just the beginning. We need to factor in B-cell and anti-
body mediated issues using structural data. We need to
properly assess the role of aggregation, of expression
levels, of post-translationald a n g e rs i g n a l sa n dt h ep o s -
session of pathogen-derived PAMPs, as well as the abil-
ity of large molecule and small molecule adjuvants to
raise the intrinsic immunogenicity of candidates to use-
ful levels. We should note in passing that many host-
derived molecules are also labelled PAMPs; these
include fibronectin, HSP70, and heparan sulphate,
amongst others. However, these molecules are endogen-
ous activators of innate immunity and not relevant to
this discussion, though they may figure in auto-immune
scenarios.
Conclusions
Vaccines are a good thing; putting caveats and cavils to
one side, no one sensible really doubts the truth of this
statement. Vaccines have proved their worth time and
again, but for them to continue to prove their worth we
must find new ways of making them. Almost all pre-
sent-day vaccines are mediated by antibodies, and the
majority target viral diseases. Unfortunately, we are now
running short of target diseases which fit this restrictive
bill. Many of the pathogens responsible for current
recalcitrant and emergent diseases are, and are set to
prove, much more demanding and difficult to target. In
many senses, the low hanging fruit has been cut down
and now the fruit we most desire is well out of reach.
Many diseases, including the WHO’sb i gt h r e ed i s e a s e s :
HIV, TB, and Malaria, are much more complicated
functionally and/or structurally, and cellular, as opposed
to humoral, immunology is tasked with defence against
these dark arts.
Peptide vaccines and those based on APCs are impor-
tant new if as yet unspectacular directions for research
in vaccine discovery, yet modern strategies for vaccine
Figure 3 Factors underlying Immunogenicity As elaborated in the text, the phenomenon of Immunogenicity can be explored through the
diversity of underlying individual factors contributing to the instigation of the immune response. These factors can be assigned to the host
(epitope recognition), the pathogen (location and expression level), and also factors intrinsic to the protein antigen itself, such as the possession
of post-translational danger signals.
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for vaccine antigens, at least for the proactive search for
vaccines targeting long-standing but untreated diseases
rather than the reactive response to so-called pan-
demics. Such antigens, once discovered, will, in time,
and with careful manipulation and an appropriate deliv-
ery system and/or appropriate adjuvant, become first
candidate subunit vaccines and, after proper clinical eva-
luation, the vaccines of tomorrow. There are, as we have
outlined, many competing ideas, thoughts, and concepts
that can help us in our quest. Certain of these hypoth-
esis we have had cause to outline, are indubitably per-
suasive, even compellingly convincing, yet in execution
many such methods fall far short of our desires. No sin-
gle approach, however promising, is able to deliver on
its promise.
The reason for this failure is comparatively simple if
uncompromisingly unsatisfying; as we are dealing with
over simplified abstractions, we cannot hope to capture
what is necessary for prediction by looking in a rela-
tively superficial way at a single contributory factor,
since protein immunogenicity arises from many, many
factors. This is not a bioinformatics problem that is
easily solved; instead it is like protein secondary struc-
ture prediction which has resisted all attempts over
many decades, so obscure and recondite and far
removed from direct experience a problem as it is. Fac-
tors mediating protein immunogenicity are many and
include host-side properties - possession of B or T cell
epitopes for example - and pathogen-side properties -
protein expression levels and sub-cellular location - as
well as its aggregation state and the possession of post-
translational danger signals. A candidate vaccine should
be highly expressed, available for immune surveillance,
and possess epitopes that the host recognises. Predicting
such diverse properties remains challenging, though sev-
eral contributing factors can be reliably predicted.
Yet, no one factor is itself enough. What we need is
an integrative, systems biology approach to the problem.
A st h ep o e tM a y aA n g e l o us on e a t l yp u t si t :“We all
should know that diversity makes for a rich tapestry,
a n dw em u s tu n d e r s t a n dt h a ta l lt h et h r e a d so ft h e
tapestry are equal in value no matter what their colour.”
No one method is universally applicable and successful;
rather we need to integrate several equally-valid,
equally-partial methods and draw from their synergy,
useful, helpful data. This is the as yet unattained goal;
yet as these are issues of such importance even a partial
solution would be prize enough.
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